Waters (WAT) Q4 2010 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2010 earnings summary
15 Oct, 2026Executive summary
2010 results exceeded expectations, returning to double-digit sales growth and close to 20% growth in adjusted EPS; Q4 sales rose 13% YoY and adjusted EPS increased 23%.
Broad end-market recovery and strong uptake of new instrument systems supported results; early 2011 demand and customer response remained encouraging.
Financial highlights
Q4 non-GAAP diluted EPS rose 23% to $1.38 from $1.12; GAAP diluted EPS was $1.36 versus $1.08 YoY.
Q4 sales increased 13% before currency translation, which was approximately neutral; full-year free cash flow was $409M versus $372M in 2009.
Q4 free cash flow was $127M versus $112M YoY, after $16M CapEx and specified non-cash tax and UK project adjustments.
Full-year operating income as a percent of sales improved 70 bps; full-year EPS grew 19%, aided by tax benefits and share repurchases.
Outlook and guidance
FY2011 sales growth expected in the high single digits, including ~1 point from FX; gross margin expected to rise 30–40 bps and operating expenses to grow slightly slower than sales.
FY2011 non-GAAP diluted EPS guidance is $4.60–$4.70; operating tax rate expected at 16%–16.5%, and average diluted shares expected to fall by ~2M.
Q1 organic sales growth expected at 8%–9%; FX at current levels expected to add ~1 point, for reported growth of 9%–10%; non-GAAP EPS guidance is $0.90–$0.95.
FY2011 free cash flow expected to approach $450M, excluding the UK facility; forecast includes ~$510M cash from operations and ~$60M CapEx.
Q1 Japan sales expected to decline modestly, reflecting a strong prior-year finish and stimulus spending; decline is included in guidance.
Latest events from Waters
- Core demand lifted Q3 revenue 9% constant currency as FX constrained reported growth.WAT
Q3 2015 - Pharma delays and India weakness slowed Q1; FY outlook still targets 2%-4% reported growth.WAT
Q1 2012 - Q2 growth outpaced expectations, with AI, innovation, and integration driving strong future outlook.WAT
U.S. All Stars Conference - Momentum from innovation, localization, and integration supports high single-digit growth outlook.WAT
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue doubled on BDS acquisition, but acquisition costs led to operating losses.WAT
Q2 2026 - Growth is fueled by innovation, premium pricing, and expanding global regulatory drivers.WAT
Leerink’s Global Healthcare Conference 2025 - Double-digit growth, innovation, and integration drive strong performance and future momentum.WAT
Jefferies Global Healthcare Conference 2026 - Q1 2026 revenue hit $1.267B with 20% EPS growth, but net loss was $72M from acquisition costs.WAT
Q1 2026 - High single-digit growth and margin expansion targeted, fueled by innovation and high-growth adjacencies.WAT
Investor Day 2025